Jamie Smith
Media Relations
Email: jamie.smith@molnlycke.com
Phone: +46 723 757507
Gothenburg, Sweden, 26 June 2025. Mölnlycke Health Care, a global leader in MedTech, today announces its largest investment to date: a €115 million expansion of its wound care manufacturing capacity in Brunswick, Maine, USA.
Rendering of facility by SMRT.
This move is a key part of Mölnlycke’s ongoing localisation strategy, aimed at producing products where they are sold. It addresses increasing US customer demand and underscores Mölnlycke's commitment to growth, customer centricity and sustainability.
Zlatko Rihter, CEO of Mölnlycke, says: "This expansion strengthens our US presence and our mission to free patients and caregivers from the burden of wounds. With increased manufacturing capacity, we’re ready to meet the growing needs of our customers and take our US growth to the next level."
Over the next five years, Mölnlycke will invest around €115 million to secure the supply of Mölnlycke's life-changing wound care products in the world’s largest medtech market. The expansion will create new job opportunities, increasing the local workforce by 10%, as well as engaging local contractors.
By expanding its US manufacturing capacity, Mölnlycke will strengthen its supply chain resilience, mitigate risk exposure and ensure the timely delivery of products to healthcare providers and patients across the US and beyond.
The state-of-the-art facility will support Mölnlycke’s long-term sustainability goals by utilising renewable energy sources like wind and solar power and reducing climate impact through streamlined logistics.
Additionally, the expansion will integrate cutting-edge machinery and technical equipment from US suppliers to enable high quality and efficient production of advanced wound care products.
Chris Biddle, General Manager US Manufacturing, Wound Care, Mölnlycke, says, “This expansion is a very big deal and the result of over a year’s hard work. Besides creating new jobs, it will drive workforce development and bring technological advancements. It’s a win for Mölnlycke, for the local community and for patients. We’re excited about the positive impact it will have locally in Maine and across the broader US healthcare landscape.”
For more information, please contact
Media Relations
Email: jamie.smith@molnlycke.com
Phone: +46 723 757507
Stockholm/Gothenburg – 24 June, 2025. Mölnlycke Health Care and The Swedish Export Credit Corporation (SEK) have signed a USD 400 million financing agreement to support the healthcare company’s continued global growth and development.
New white paper calls for integration of environmental, human and economic metrics in sustainability assessments of medical technologies.
Gothenburg, Sweden. 21 May 2025 – Mölnlycke Health Care, a global leader in MedTech, has officially opened its new global headquarters at GoCo Health Innovation City in Gothenburg, Sweden—a major milestone in its journey to drive sustainable healthcare innovation.
Gothenburg, Sweden. 13 May, 2025. Mölnlycke’s long-term net zero greenhouse gas (GHG) emission reduction targets have been validated by the Science Based Targets initiative (SBTi), following prior validation of the company’s near-term GHG emission reduction targets.
Gothenburg, Sweden. May 02, 2025. The Wound Care Collaborative Community (WCCC) is leading a groundbreaking initiative looking to develop a standardised pre-clinical testing framework for wound dressings.
Gothenburg, Sweden. 1 April 2025. Today Mölnlycke Health Care has published its Annual report for 2024, including the sustainability report.